Top-Rated StocksTop-RatedNASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis $1.19 -0.05 (-3.95%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cabaletta Bio Stock (NASDAQ:CABA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cabaletta Bio alerts:Sign Up Key Stats Today's Range$1.14▼$1.2350-Day Range$1.17▼$2.7152-Week Range$1.15▼$19.04Volume628,558 shsAverage Volume1.49 million shsMarket Capitalization$58.41 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingBuy Company OverviewCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More… Remove Ads Cabaletta Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCABA MarketRank™: Cabaletta Bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 465th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cabaletta Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.34) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.14% of the float of Cabaletta Bio has been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 7.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.14% of the float of Cabaletta Bio has been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 7.84%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.19 News SentimentCabaletta Bio has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Stock News HeadlinesCabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC WainwrightApril 3 at 3:41 AM | americanbankingnews.comGuggenheim Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA)April 3 at 3:41 AM | americanbankingnews.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 3, 2025 | Premier Gold Co (Ad)Cabaletta Bio price target lowered to $13 from $26 at StifelApril 2 at 3:07 PM | markets.businessinsider.comCabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial ResultsApril 2 at 10:06 AM | msn.comMorgan Stanley Has Lowered Expectations for Cabaletta Bio (NASDAQ:CABA) Stock PriceApril 2 at 4:17 AM | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Price Target Lowered to $3.00 at Wells Fargo & CompanyApril 2 at 2:51 AM | americanbankingnews.comCabaletta Bio Advances T Cell Therapies for Autoimmune DiseasesApril 2 at 12:12 AM | tipranks.comSee More Headlines CABA Stock Analysis - Frequently Asked Questions How have CABA shares performed this year? Cabaletta Bio's stock was trading at $2.27 on January 1st, 2025. Since then, CABA shares have decreased by 46.9% and is now trading at $1.2050. View the best growth stocks for 2025 here. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01. When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an IPO on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/08/2024Today4/03/2025Next Earnings (Estimated)4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CABA CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$50.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,674.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.10% Return on Assets-45.49% Debt Debt-to-Equity RatioN/A Current Ratio8.11 Quick Ratio8.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.51 per share Price / Book0.23Miscellaneous Outstanding Shares48,877,000Free Float44,048,000Market Cap$60.61 million OptionableOptionable Beta2.58 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CABA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.